CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including:

• Genomic testing options for assessing risk of recurrence
• Adjuvant treatment duration and holidays with CDK4/6 inhibitors
• Managing renal toxicities, prophylaxis for DVT, and asymptomatic ILD
• CDK4/6 inhibitors with inavolisib and fulvestrant

Presenters:
William J. Gradishar, MD, FACP, FASCO
Betsy Bramsen Professor of Breast Oncology
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Heather McArthur, MD, MPH, FASCO
Professor, Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

Joanne Mortimer, MD, FACP, FASCO
Vice Chair, Medical Oncology
Professor, Division of Medical Oncology & Experimental Therapeutics
Associate Director for Education and Training
Baum Family Professor of Women’s Cancers
City of Hope Comprehensive Cancer Center
Duarte, California

Link to full program:
https://bit.ly/4osHLTm

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.